Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cost-effectiveness targeting CLL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Treatment of monogenic disorders with viral transduced haematopoietic stem cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hæmatopoietisk stamcellebehandling

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiUndervisning

  • Brian Kornblit
  • Barry E Storer
  • Niels S Andersen
  • Michael B Maris
  • Thomas R Chauncey
  • Effie W Petersdorf
  • Ann E Woolfrey
  • Mary E D Flowers
  • Rainer Storb
  • David G Maloney
  • Brenda M Sandmaier
Vis graf over relationer

This trial aimed to evaluate the efficacy of sirolimus in addition to cyclosporine (CSP) and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis after nonmyeloablative conditioning for HLA class I or II mismatched hematopoietic cell transplantation (HCT). Eligible patients had hematologic malignancies treatable by allogeneic HCT. Conditioning consisted of fludarabine (90 mg/m2) and 2 to 3 Gy total body irradiation. GVHD prophylaxis comprised cyclosporine, mycophenolate mofetil, and sirolimus. The primary objective was to determine whether the cumulative incidence of grade 2 to 4 acute GVHD could be reduced to <70% in HLA class I or II mismatched HCT. The study was closed on December 20, 2018. Seventy-seven participants were recruited between April 14, 2011, and December 12, 2018, of whom 76 completed the study intervention. Median follow-up was 47 months (range, 4-94 months). The cumulative incidence of grade 2 to 4 acute GVHD at day 100 was 36% (95% confidence interval [CI], 25-46), meeting the primary end point. The cumulative incidence of nonrelapse morality, relapse/progression, and overall survival was 18% (95% CI, 9-27), 30% (interquartile range, 19-40), and 62% (95% CI, 50-73) after 4 years. In conclusion, the addition of sirolimus to cyclosporine and mycophenolate mofetil resulted in a lower incidence of acute GVHD, thus translating into superior overall survival compared with historical results. This trial was registered at www.clinicaltrials.gov as #NCT01251575.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind136
Udgave nummer13
Sider (fra-til)1499-1506
Antal sider8
ISSN0006-4971
DOI
StatusUdgivet - 24 sep. 2020

ID: 61675978